TEL AVIV, Israel, May 6, 2011 /PRNewswire/ — InspireMD, Inc.
(OTC BB: NSPR) (“Inspire” or the “Company”), the developer of the
MGuard™ mesh protective stent system, today announced that
Mr. Ofir Paz, InspireMD’s co-founder and chief executive officer,
and Mr. Craig Shore, chief financial officer, will participate in
the Benchmark Company, LLC One-on-One Investor Conference on
Thursday, May 12, 2011 at The Pfister Hotel, 424 East Wisconsin
Ave., Milwaukee, Wis. The conference will include a number of
one-on-one meetings arranged by Benchmark with investors. Investors
planning to attend the conference should contact their Benchmark
representative to arrange a meeting.
Management will discuss its proprietary stent platform
technology: MGuard™, featuring a patent-pending micron mesh
technology that wraps a stent, reducing Major Adverse Cardiac
Events [MACE] by filtering debris and minimizing vessel injury by
distributing strut pressure. MGuard™ has been implanted in
thousands of patients with encouraging clinical results in Europe
and Latin America. MGuard™ is a solution for high-risk Acute
Coronary Syndrome (heart attack) patients — a market of over
two million patients per year. The presentations will also discuss
the Company’s ongoing clinical efforts, including a randomized
trial in Europe, Latin America and South Africa, chaired by Dr.
Gregg Stone, to support its regulatory approval efforts, and its
focus on securing FDA approval to sell its products in the U.S.,
including its collaboration with the Harvard Clinical Research
Institute (HCRI), an international leader in design and conduct of
coronary device trials, for U.S. FDA trials.
About The Benchmark Company, LLC
Headquartered in New York City, The Benchmark Company, LLC is an
institutional brokerage firm with a strong sales/trading presence
in addition to its rapidly expanding research and investment
banking arms. In just nine years, Benchmark has e